ROX評分預測新型冠狀病毒病人使用高流量鼻導管之成功率

ROX index as predictor high flow nasal cannula therapy success in acute respiratory failure due to Covid-19

10.6269/JRT.202407_23(2).0001

蘇育萱(Yu-Hsuan, Su)；胡漢忠(Han-Chung Hu)；黃靜芝(Ching-Tzu Huang)

新型冠狀病毒 ； 高流量鼻導管 ； ROX評分 ； 呼吸衰竭 ； Coronavirus Disease-2019 (COVID-19) ； High flow nasal cannula (HFNC) ； ROX index ； Respiratory failure

呼吸治療

23卷2期（2024 / 07 / 01）

1 - 14

繁體中文;英文

前言：2019新型冠狀病毒疾病（Coronavirus Disease 2019, COVID-19）疫情自2019年底從中國大陸武漢地區開始爆發，迅速蔓延至全球各地，亦對我國造成嚴重的影響。隨著疫情的發展，醫療資源分配最佳化更顯重要，順應潮流，高流量鼻導管（high flow nasal cannula, HFNC）成為廣為討論的對象。研究方法：本研究為回溯性觀察研究，於2022年5月至2022年12月，因感染新型冠狀病毒，收治在北部某醫學中心專責病房，使用HFNC，符合全民健保適應症之病人。蒐集使用相關數據，利用ROX評分（ROX index）進行分析。研究結果：本研究一共收案115人，排除未符合條件16人，總計99人進行研究統計。成功組73人；失敗組26人。將第一、第二、第六、第十二小時ROX評分進行分析，結果顯示僅第十二小時的結果最具顯著差異。結論與建議：本研究與過去文獻結果相同，ROX評分能預測HFNC使用成效。但結果與過去研究相比，準確性較低且計算出的ROX評分數值也較高。因此建議，未來從事相關研究，增加收案數，並利用不同適應症進行分層分析。以利更準確得知ROX評分之適用族群，是否適用於確診新型冠狀病毒疾病使用HFNC病人。

Introduction: The Coronavirus Disease 2019 (COVID-19) outbreak originated in Wuhan, China at the end of 2019 and quickly spread globally, significantly impacting countries worldwide, including ours. As the pandemic evolved, optimizing healthcare resource allocation became crucial, and high flow nasal cannula (HFNC) emerged as a widely discussed intervention. Methods: This study was a retrospective observational study conducted from May 2022 to December 2022 in the isolation ward at a medical center in the northern region. The study included COVID-19 patients who were admitted and treated with HFNC. Relevant data were collected, and analysis was performed using the ROX index scoring system. Results: A total of 115 patients were initially enrolled in this study, with 16 individuals excluded for not meeting the criteria, resulting in a final sample size of 99 patients for statistical analysis. Among them, 73 patients were classified as the successful group, while 26 patients were classified as the failure group. Analysis of the ROX index scoring at the first, second, sixth, and twelfth hour revealed that only the results at the twelfth hour showed significant differences between the two groups. Conclusion and Recommendations: The findings of this study align with previous literature, indicating that the ROX index can predict the effectiveness of HFNC therapy. However, the accuracy of the results and the calculated ROX index values were lower compared to previous studies. Therefore, it is recommended for future research to increase the sample size and conduct stratified analyses based on different indications. This will provide a more accurate understanding of the applicable population for the ROX index and its suitability for COVID-19 patients using HFNC therapy.